Healthcare
Live Price
Offline$19.70
-0.20% today
1Y Change
-24.68%
Window
Jun 20, 2025 → Jun 12, 2026
Coverage: 246 bars · Jun 20, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Siemens Healthineers AG (SMMNY) is a Healthcare stock with a market cap of $38.95B and listed on PNK. The stock last traded around $19.70 and down 24.7% across the available one-year price window (Jun 20, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -1.5%, EPS growth of +3.4%, a dividend yield of 2.9%. What stands out right now is revenue -1.5%, EPS +3.4%, free cash flow +20.4% with operating margin 14.7% and ROIC 7.3%. The dividend matters to the case here, with a current yield around 2.9%. Valuation is more restrained than many high-expectation growth names at P/E 18.4 and price/sales 1.7. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines SMMNY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SMMNY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SMMNY Max Drawdown
-32.74%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SMMNY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$18.0B
-17.1% YoY
FY Net Income
$1.7B
-15.3% YoY
Free Cash Flow
$2.1B
+50.2% YoY
Revenue Growth
-1.5%
EPS Growth
+3.4%
Gross Margin
38.4%
Net Margin
9.1%
Income statement
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 22.0B | 22.4B | 21.7B | 21.7B | 18.0B |
| Gross Profit | 8.5B | 8.5B | 7.7B | 8.1B | 7.0B |
| Operating Income | 3.2B | 3.3B | 2.4B | 3.1B | 2.8B |
| EBITDA | 4.3B | 4.2B | 3.8B | 4.3B | 3.5B |
| Net Income | 2.0B | 1.9B | 1.5B | 2.0B | 1.7B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2.2B | 2.7B | 1.6B | 1.4B | 1.3B |
| Total Assets | 52.1B | 46.1B | 46.7B | 49.1B | 41.9B |
| Total Liabilities | 30.9B | 27.8B | 28.6B | 29.2B | 25.9B |
| Shareholder Equity | 21.2B | 18.2B | 18.1B | 19.8B | 16.0B |
| Total Debt | 17.7B | 16.2B | 16.7B | 16.7B | 14.3B |
| Net Debt | -1.4B | 13.5B | 15.0B | 15.2B | 13.0B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2.8B
+23.4% YoY
Capital Expenditures
674M
+20.9% YoY
Free Cash Flow
2.1B
+50.2% YoY
Key ratios
Gross Margin
38.4%
Operating Margin
14.7%
Net Margin
9.1%
ROE
11.6%
Debt / Equity
0.82x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.